Dentsply Sirona (XRAY) Stock Outlook: Analyst Maintains Outperform Rating and $21 Price Target

Barrington Research analyst Michael Petusky reaffirms his "Outperform" rating for Dentsply Sirona (XRAY) with a price target of $21.00. The average target price for XRAY is $18.08, indicating a 14.49% upside from the current price. The average brokerage recommendation is 2.7, indicating a "Hold" status. GuruFocus estimates the GF Value for XRAY in one year at $31.59, suggesting a 100% upside from the current price.

In a recent report, Barrington Research analyst Michael Petusky reaffirmed his "Outperform" rating for Dentsply Sirona (XRAY), with a price target of $21.00. This rating comes amidst significant leadership changes and positive financial outlooks for the company. The average target price for XRAY is $18.08, indicating a 14.49% upside from the current price. The average brokerage recommendation is 2.7, indicating a "Hold" status. GuruFocus estimates the GF Value for XRAY in one year at $31.59, suggesting a 100% upside from the current price.

The reaffirmation of the rating is largely due to the appointment of Daniel Scavilla as the new CEO of Dentsply Sirona, effective August 1, 2025. Scavilla brings over 30 years of experience in the medical technology sector, previously serving as CEO of Globus Medical and holding key roles at Johnson & Johnson. His extensive experience in commercial growth and operational excellence is expected to drive Dentsply Sirona’s transformation and long-term success [3].

Petusky cited Scavilla’s appointment and the company's strong financial outlook as key factors in maintaining the "Outperform" rating. The company has preannounced solid second-quarter results, with expected revenue and adjusted EPS surpassing previous estimates. The reaffirmation of the financial guidance for FY/25 further supports confidence in the company’s future performance [2].

Despite the positive outlook, Dentsply Sirona faces several challenges. The company reported a 4.4% decline in organic sales due to a negative 4% impact from Byte. Additionally, organic sales in the US declined by 14.9%, primarily due to a negative impact from Byte and declines in CAD/CAM and IPS segments. The Orthodontic and Implant Solutions segment experienced a significant organic sales decline of 17.7%, with a notable impact from the loss of a DSO customer in the US. However, the company has maintained its 2025 outlook for organic sales and adjusted EPS, with an increased outlook for reported sales due to favorable foreign currency translation changes [1].

In conclusion, while Dentsply Sirona faces several headwinds, the appointment of Daniel Scavilla as CEO and the company's strong financial outlook suggest a promising future. Investors should closely monitor the upcoming detailed financial disclosures and business performance reports from Dentsply Sirona for further insights.

References:
[1] https://www.gurufocus.com/news/2990406/dentsply-sirona-xray-appoints-new-ceo-effective-august-2025-xray-stock-news
[2] https://www.tipranks.com/news/ratings/dentsply-sirona-buy-rating-affirmed-amid-leadership-change-and-strong-financial-outlook-ratings
[3] https://www.gurufocus.com/news/2990240/dentsply-sirona-appoints-daniel-scavilla-as-chief-executive-officer-xray-stock-news